• Something wrong with this record ?

Dienogest 2 mg Daily in the Treatment of Adolescents with Clinically Suspected Endometriosis: The VISanne Study to Assess Safety in ADOlescents

AD. Ebert, L. Dong, M. Merz, B. Kirsch, M. Francuski, B. Böttcher, H. Roman, P. Suvitie, O. Hlavackova, K. Gude, C. Seitz,

. 2017 ; 30 (5) : 560-567. [pub] 20170209

Language English Country United States

Document type Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc18016772

STUDY OBJECTIVE: To study the safety and efficacy of dienogest 2 mg in adolescents with suspected endometriosis. DESIGN: A 52-week, open-label, single-arm study. SETTING: In 21 study centers, in 6 European countries. PARTICIPANTS: Adolescents aged 12 to younger than 18 years with clinically suspected or laparoscopically confirmed endometriosis. INTERVENTIONS: Dienogest 2 mg once daily. MAIN OUTCOME MEASURES: The primary end point was relative change in lumbar spine (L2-L4) bone mineral density (BMD) measured using dual-energy x-ray absorptiometry. A key secondary end point was change in endometriosis-associated pain assessed using a visual analogue scale. RESULTS: Of 120 patients screened, 111 comprised the full-analysis set (ie, patients who took ≥1 dose of study drug and had ≥1 post-treatment observation) and 97 (87.4%) completed the study. Mean lumbar BMD at baseline was 1.1046 (SD, 0.1550) g/cm2. At the end of dienogest treatment (EOT; defined as at 52 weeks or premature study discontinuation), mean relative change in BMD from baseline was -1.2% (SD, 2.3%; n = 103). Follow-up measurement 6 months after EOT in the subgroup with decreased BMD at EOT (n = 60) showed partial recovery in lumbar BMD (mean change from baseline: -2.3% at EOT, -0.6% 6 months after EOT). Mean endometriosis-associated pain score was 64.3 (SD, 19.1) mm at baseline and decreased to 9.0 (SD, 13.9) mm by week 48. CONCLUSION: In adolescents with suspected endometriosis, dienogest 2 mg for 52 weeks was associated with a decrease in lumbar BMD, followed by partial recovery after treatment discontinuation. Endometriosis-associated pain was substantially reduced during treatment. Because bone accretion is critical during adolescence, results of the VISanne study to assess safety in ADOlescents (VISADO) study highlights the need for tailored treatment in this population, taking into account the expected efficacy on endometriosis-associated pain and an individual's risk factors for osteoporosis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016772
003      
CZ-PrNML
005      
20180521134651.0
007      
ta
008      
180515s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jpag.2017.01.014 $2 doi
035    __
$a (PubMed)28189702
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ebert, Andreas D $u Praxis for Women's Health, Gynecology & Obstetrics, Berlin, Germany. Electronic address: info@prof-ebert.de.
245    10
$a Dienogest 2 mg Daily in the Treatment of Adolescents with Clinically Suspected Endometriosis: The VISanne Study to Assess Safety in ADOlescents / $c AD. Ebert, L. Dong, M. Merz, B. Kirsch, M. Francuski, B. Böttcher, H. Roman, P. Suvitie, O. Hlavackova, K. Gude, C. Seitz,
520    9_
$a STUDY OBJECTIVE: To study the safety and efficacy of dienogest 2 mg in adolescents with suspected endometriosis. DESIGN: A 52-week, open-label, single-arm study. SETTING: In 21 study centers, in 6 European countries. PARTICIPANTS: Adolescents aged 12 to younger than 18 years with clinically suspected or laparoscopically confirmed endometriosis. INTERVENTIONS: Dienogest 2 mg once daily. MAIN OUTCOME MEASURES: The primary end point was relative change in lumbar spine (L2-L4) bone mineral density (BMD) measured using dual-energy x-ray absorptiometry. A key secondary end point was change in endometriosis-associated pain assessed using a visual analogue scale. RESULTS: Of 120 patients screened, 111 comprised the full-analysis set (ie, patients who took ≥1 dose of study drug and had ≥1 post-treatment observation) and 97 (87.4%) completed the study. Mean lumbar BMD at baseline was 1.1046 (SD, 0.1550) g/cm2. At the end of dienogest treatment (EOT; defined as at 52 weeks or premature study discontinuation), mean relative change in BMD from baseline was -1.2% (SD, 2.3%; n = 103). Follow-up measurement 6 months after EOT in the subgroup with decreased BMD at EOT (n = 60) showed partial recovery in lumbar BMD (mean change from baseline: -2.3% at EOT, -0.6% 6 months after EOT). Mean endometriosis-associated pain score was 64.3 (SD, 19.1) mm at baseline and decreased to 9.0 (SD, 13.9) mm by week 48. CONCLUSION: In adolescents with suspected endometriosis, dienogest 2 mg for 52 weeks was associated with a decrease in lumbar BMD, followed by partial recovery after treatment discontinuation. Endometriosis-associated pain was substantially reduced during treatment. Because bone accretion is critical during adolescence, results of the VISanne study to assess safety in ADOlescents (VISADO) study highlights the need for tailored treatment in this population, taking into account the expected efficacy on endometriosis-associated pain and an individual's risk factors for osteoporosis.
650    _2
$a absorpční fotometrie $7 D015502
650    _2
$a mladiství $7 D000293
650    _2
$a kostní denzita $x účinky léků $7 D015519
650    _2
$a dítě $7 D002648
650    _2
$a endometrióza $x farmakoterapie $7 D004715
650    _2
$a Evropa $7 D005060
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a antagonisté hormonů $x škodlivé účinky $x terapeutické užití $7 D006727
650    _2
$a lidé $7 D006801
650    _2
$a bederní obratle $7 D008159
650    _2
$a nandrolon $x škodlivé účinky $x analogy a deriváty $x terapeutické užití $7 D009277
650    _2
$a měření bolesti $7 D010147
650    _2
$a pánevní bolest $x farmakoterapie $7 D017699
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Dong, Liying $u Bayer AG, Berlin, Germany.
700    1_
$a Merz, Martin $u Bayer AG, Berlin, Germany.
700    1_
$a Kirsch, Bodo $u Bayer AG, Berlin, Germany.
700    1_
$a Francuski, Maja $u Bayer AG, Berlin, Germany.
700    1_
$a Böttcher, Bettina $u Department of Gynecologic Endocrinology and Reproductive Medicine, Medical University Innsbruck, Innsbruck, Austria.
700    1_
$a Roman, Horace $u Department of Gynecology and Obstetrics, Rouen University Hospital, Rouen, France; Research Group 4308 'Spermatogenesis and Gamete Quality', Reproductive Biology Laboratory, Rouen University Hospital, Rouen, France.
700    1_
$a Suvitie, Pia $u Department of Obstetrics and Gynecology, University of Turku and Turku University Hospital, Turku, Finland.
700    1_
$a Hlavackova, Olga $u Gynaecological Rehabilitation Center, Budějovické předměstí, Písek, Czech Republic.
700    1_
$a Gude, Kerstin $u Bayer AG, Berlin, Germany.
700    1_
$a Seitz, Christian $u Bayer AG, Berlin, Germany.
773    0_
$w MED00005128 $t Journal of pediatric and adolescent gynecology $x 1873-4332 $g Roč. 30, č. 5 (2017), s. 560-567
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28189702 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180521134833 $b ABA008
999    __
$a ok $b bmc $g 1300396 $s 1013612
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 30 $c 5 $d 560-567 $e 20170209 $i 1873-4332 $m Journal of pediatric & adolescent gynecology $n J Pediatr Adolesc Gynecol $x MED00005128
LZP    __
$a Pubmed-20180515

Find record

Citation metrics

Archiving options